DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Clancy JP, Rowe SM, Accurso FJ et al.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Thorax 2012;
67: 12-18
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.